This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Langer, S. W. Articles by Jensen, P. B. Search for Related Content PubMed PubMed Citation Articles by Langer, S. W. Articles by Jensen, P. B.

Treatment of Anthracycline Extravasation with Dexrazoxane¹

The Laboratory of Experimental Medical Oncology, The Finsen and Laboratory Centers, National University Hospital, DK-2100 Copenhagen, Denmark

Accidental extravasation of anthracyclines is a feared complication. Present treatment consists of local cooling and extensive surgical debridement, which often results in severe morbidity. All clinically important anthracyclines are topoisomerase II poisons that are antagonized by topoisomerase II catalytic inhibitors such as dexrazoxane. Therefore, we investigated whether dexrazoxane protects against extravasation lesions caused by anthracyclines. B6D2F1 mice received s.c. daunorubicin, doxorubicin, or idarubicin followed by systemic treatment with dexrazoxane or saline. One single systemic dose of dexrazoxane immediately after s.c. administration of doxorubicin, daunorubicin, or idarubicin reduced the tissue lesions (expressed as area under the curve of wound size times duration) by 96% (P < 0.0001), 70% (P < 0.0001), and 87% (P = 0.0004), respectively. Moreover, the treatment resulted in a statistically significant reduction in the fraction of mice with wounds as well as the duration of wounds. The induction of wounds was dose-dependent, as was the degree of protection by dexrazoxane. Dexrazoxane could be administered up to 3 h after the anthracycline without loss of protection. Triple-dosage of dexrazoxane tended to be more effective than a single injection. Dexrazoxane had no effect on lesions induced by hydrogen peroxide. This is the first report of use of a topoisomerase II catalytic inhibitor such as dexrazoxane in the treatment of anthracycline extravasation injuries. These convincing preclinical data represent a novel nontoxic approach that can easily be implemented into the clinical handling of accidental extravasation of anthracyclines.

This article has been cited by other articles:

				R. C. Kane, W. D. McGuinn Jr, R. Dagher, R. Justice, and R. Pazdur Dexrazoxane (TotectTM): FDA Review and Approval for the Treatment of Accidental Extravasation Following Intravenous Anthracycline Chemotherapy Oncologist, April 1, 2008; 13(4): 445 - 450. [Abstract] [Full Text] [PDF]

				M. Grauslund, A. V. Thougaard, A. Fuchtbauer, K. F. Hofland, P. H. Hjorth, P. B. Jensen, M. Sehested, E.-M. Fuchtbauer, and L. H. Jensen A Mouse Model for Studying the Interaction of Bisdioxopiperazines with Topoisomerase II{alpha} in Vivo Mol. Pharmacol., October 1, 2007; 72(4): 1003 - 1014. [Abstract] [Full Text] [PDF]

				D. Reeves Management of Anthracycline Extravasation Injuries Ann. Pharmacother., July 1, 2007; 41(7): 1238 - 1242. [Abstract] [Full Text] [PDF]

				H. Mouridsen, S. Langer, J Buter, H Eidtmann, G Rosti, M de Wit, P Knoblauch, A Rasmussen, K Dahlstrom, P. Jensen, et al. Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies Ann. Onc., March 1, 2007; 18(3): 546 - 550. [Abstract] [Full Text] [PDF]

				D. H. Thamm and D. M. Vail Aftershocks of Cancer Chemotherapy: Managing Adverse Effects J. Am. Anim. Hosp. Assoc., January 1, 2007; 43(1): 1 - 7. [Abstract] [Full Text] [PDF]

				M. C. Hooke Clinical Nurse Specialist and Evidence-Based Practice: Managing Anthracycline Extravasation Journal of Pediatric Oncology Nursing, September 1, 2005; 22(5): 261 - 264. [Abstract] [PDF]

				A. Renodon-Corniere, T. K. Sorensen, P. B. Jensen, J. L. Nitiss, B. Sokilde, M. Sehested, and L. H. Jensen Probing the Role of Linker Substituents in Bisdioxopiperazine Analogs for Activity against Wild-Type and Mutant Human Topoisomerase IIalpha Mol. Pharmacol., May 1, 2003; 63(5): 1159 - 1168. [Abstract] [Full Text] [PDF]

				L. H. Jensen, A. Renodon-Corniere, I. Wessel, S. W. Langer, B. Sokilde, E. V. Carstensen, M. Sehested, and P. B. Jensen Maleimide Is a Potent Inhibitor of Topoisomerase II in Vitro and in Vivo: A New Mode of Catalytic Inhibition Mol. Pharmacol., May 1, 2002; 61(5): 1235 - 1243. [Abstract] [Full Text] [PDF]